Literature DB >> 21484966

Curcumin for clinical and endoscopic remission in ulcerative colitis.

Conor Lahiff, Alan C Moss.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21484966     DOI： 10.1002/ibd.21710

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN： 1078-0998            Impact factor:   5.325


× No keyword cloud information.
  15 in total

1.  Oral administration of pH-sensitive curcumin-loaded microparticles for ulcerative colitis therapy.

Authors:  Bo Xiao; Xiaoying Si; Mingzhen Zhang; Didier Merlin
Journal:  Colloids Surf B Biointerfaces       Date:  2015-08-01       Impact factor: 5.268

2.  Oral delivery of curcumin via porous polymeric nanoparticles for effective ulcerative colitis therapy.

Authors:  Qiubing Chen; Xiaoying Si; Lijun Ma; Panpan Ma; Meili Hou; Shuang Bai; Xiaoshuai Wu; Ying Wan; Bo Xiao; Didier Merlin
Journal:  J Mater Chem B       Date:  2017-05-05       Impact factor: 6.331

Review 3.  Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases.

Authors:  Ajaikumar B Kunnumakkara; Devivasha Bordoloi; Ganesan Padmavathi; Javadi Monisha; Nand Kishor Roy; Sahdeo Prasad; Bharat B Aggarwal
Journal:  Br J Pharmacol       Date:  2016-10-21       Impact factor: 8.739

Review 4.  Therapeutic roles of curcumin: lessons learned from clinical trials.

Authors:  Subash C Gupta; Sridevi Patchva; Bharat B Aggarwal
Journal:  AAPS J       Date:  2012-11-10       Impact factor: 4.009

5.  Residual inflammation and ulcerative colitis in remission.

Authors:  Alan C Moss
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-03

Review 6.  Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers.

Authors:  Bharat B Aggarwal; Subash C Gupta; Bokyung Sung
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

Review 7.  Prevention of colitis-associated cancer: natural compounds that target the IL-6 soluble receptor.

Authors:  Cate Moriasi; Dharmalingam Subramaniam; Shanjana Awasthi; Satish Ramalingam; Shrikant Anant
Journal:  Anticancer Agents Med Chem       Date:  2012-12       Impact factor: 2.505

Review 8.  Epigenetics/epigenomics and prevention by curcumin of early stages of inflammatory-driven colon cancer.

Authors:  Renyi Wu; Lujing Wang; Ran Yin; Rasika Hudlikar; Shanyi Li; Hsiao-Chen D Kuo; Rebecca Peter; Davit Sargsyan; Yue Guo; Xia Liu; A N Kong
Journal:  Mol Carcinog       Date:  2019-12-09       Impact factor: 4.784

9.  Orally delivered polycurcumin responsive to bacterial reduction for targeted therapy of inflammatory bowel disease.

Authors:  Hongzhi Qiao; Dong Fang; Jing Chen; Yuan Sun; Chen Kang; Liuqing Di; Junsong Li; Zhipeng Chen; Jun Chen; Yahan Gao
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

10.  Estimation of curcumin intake in Korea based on the Korea National Health and Nutrition Examination Survey (2008-2012).

Authors:  Youngjoo Kwon
Journal:  Nutr Res Pract       Date:  2014-09-15       Impact factor: 1.926
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.